Minimal Residual Disease Testing Market - Strategic Insights and Forecasts (2026-2031)

The Minimal Residual Disease Testing Market is set to reach USD 3.0 billion in 2031, growing at a CAGR of 7.9% from USD 2.0 billion in 2026.

The MRD testing landscape is evolving from research-centric applications to routine clinical use, particularly in oncology care pathways. The integration of MRD testing into treatment decision-making is transforming how remission and relapse risks are assessed. Technologies such as next-generation sequencing are enabling ultra-sensitive detection, while liquid biopsy approaches are reducing reliance on invasive procedures, thereby improving patient compliance and testing frequency.

A key trend shaping the market is the increasing use of MRD status as a biomarker for therapy optimization. Pharmaceutical companies are incorporating MRD endpoints into drug development pipelines to accelerate regulatory approvals. Furthermore, automation and AI-driven analytics are enhancing result interpretation, reducing turnaround times, and improving diagnostic accuracy. This technological convergence is strengthening the role of MRD testing as a standard-of-care component in oncology.

Market Dynamics

Market Drivers

• Rising Burden of Hematological Cancers: The increasing prevalence of leukemia, lymphoma, and multiple myeloma is significantly driving MRD testing demand. These cancers require continuous monitoring even after remission, as residual malignant cells can lead to relapse. MRD testing provides clinicians with actionable insights to adjust treatment regimens, improving survival outcomes and reducing unnecessary therapy exposure.

• Advancements in Molecular Diagnostic Technologies: Technological innovation is a major growth catalyst, particularly in PCR and NGS platforms. Enhanced sensitivity levels, often detecting one cancer cell among a million normal cells, are enabling earlier and more accurate relapse prediction. Continuous improvements in assay design, automation, and bioinformatics are reducing costs and expanding accessibility, making MRD testing more viable across healthcare settings.

• Increasing Adoption of Personalized Medicine: The shift toward individualized treatment strategies is accelerating MRD testing adoption. Clinicians increasingly rely on MRD results to tailor therapies, escalate or de-escalate treatment intensity, and minimize toxicity. This alignment with precision medicine frameworks enhances treatment efficiency and improves patient quality of life, making MRD testing indispensable in oncology practice.

• Regulatory Support and Clinical Integration: Growing regulatory recognition of MRD as a surrogate endpoint in clinical trials is boosting its adoption. Regulatory bodies are increasingly accepting MRD-based outcomes for drug approvals, which encourages pharmaceutical companies to integrate MRD testing into clinical development programs. This trend is reinforcing the clinical value of MRD testing and expanding its use across multiple cancer types.

Market Restraints

• High cost of advanced MRD testing technologies limits accessibility in low- and middle-income regions

• • Lack of standardized testing protocols leads to variability in results and clinical interpretation

• • Limited reimbursement coverage in certain healthcare systems restricts widespread adoption

Market Opportunities

• Expansion into Solid Tumor Applications: While MRD testing is well established in hematological malignancies, its application in solid tumors remains underpenetrated. Advancements in liquid biopsy and circulating tumor DNA analysis are enabling MRD detection in cancers such as breast, lung, and colorectal, opening new growth avenues for market players.

• Integration with Clinical Trials and Drug Development: Pharmaceutical companies are increasingly using MRD as a biomarker in clinical trials to assess treatment efficacy. This trend creates opportunities for diagnostic companies to collaborate with drug developers, offering companion diagnostics and accelerating the commercialization of MRD testing solutions.

• Emerging Markets and Healthcare Infrastructure Development: Rapid improvements in healthcare infrastructure in the Asia Pacific and other emerging regions are creating favorable conditions for MRD adoption. Government initiatives aimed at improving cancer diagnostics and increasing healthcare spending are expected to drive demand for advanced testing technologies in these markets.

• Technological Convergence and Automation: The integration of AI, machine learning, and automated workflows is enhancing MRD testing efficiency and scalability. These advancements are reducing turnaround times and operational costs, making MRD testing more accessible to a broader range of healthcare providers.

Market Segmentation

By Technology

• Polymerase Chain Reaction (PCR) dominates due to its high sensitivity, cost-effectiveness, and widespread clinical adoption in hematological malignancies

• Next-Generation Sequencing (NGS) is rapidly growing due to ultra-high sensitivity and the ability to detect complex genetic mutations with precision

• Flow Cytometry remains relevant for immunophenotyping but faces limitations in sensitivity compared to molecular methods

• Others include emerging techniques such as digital PCR and hybrid platforms offering enhanced detection capabilities

By Product Type

• Assay Kits & Reagents lead the market due to recurring demand and continuous use in diagnostic workflows

• Instruments & Services are growing steadily as laboratories invest in advanced platforms and outsource specialized testing

By Application

• Hematological Malignancies dominate due to strong clinical validation and established use in leukemia and lymphoma monitoring

• Solid Tumors are emerging as a key segment with growing adoption of liquid biopsy-based MRD detection

By End User

• Hospitals & Specialty Clinics hold a major share due to direct patient management and integration of MRD testing in treatment decisions

• Diagnostic Laboratories are expanding rapidly due to centralized testing capabilities and high-throughput processing

• Others include research institutes leveraging MRD testing for clinical studies and biomarker discovery

Regional Analysis

North America Market Analysis

North America leads the MRD testing market due to advanced healthcare infrastructure, strong adoption of precision medicine, and favorable reimbursement frameworks. The presence of leading diagnostic companies and ongoing clinical research further strengthens regional dominance.

Europe Market Analysis

Europe shows steady growth supported by increasing cancer incidence and expanding regulatory support for advanced diagnostics. Countries with strong public healthcare systems are integrating MRD testing into oncology guidelines, driving adoption.

Asia Pacific Market Analysis

Asia Pacific is the fastest-growing region, driven by rising healthcare investments, improving diagnostic capabilities, and increasing awareness of early cancer detection. Large patient populations and government initiatives are accelerating market expansion.

Rest of the World

The Rest of the World region is gradually adopting MRD testing, with growth primarily driven by improving healthcare access and increasing collaborations with global diagnostic providers.

Regulatory Landscape

The regulatory landscape for MRD testing is evolving as authorities recognize its clinical significance in oncology. Regulatory agencies are increasingly supporting the use of MRD as a surrogate endpoint in clinical trials, which accelerates drug approval processes. This shift is encouraging diagnostic companies to develop standardized and validated MRD assays that meet stringent regulatory requirements.

However, regulatory frameworks vary across regions, creating challenges in global standardization. While some regions have established clear guidelines for MRD testing, others are still in the early stages of regulatory development. Efforts toward harmonization and validation of testing protocols are critical to ensuring consistency and reliability in MRD results across different healthcare systems.

Pipeline Analysis

The MRD testing pipeline is robust, with numerous assays under development focusing on improving sensitivity, specificity, and ease of use. Companies are investing heavily in next-generation sequencing-based assays capable of detecting extremely low levels of residual disease. These innovations are particularly focused on expanding applications beyond hematological cancers into solid tumors.

Additionally, there is significant activity in developing liquid biopsy-based MRD tests that utilize circulating tumor DNA. These approaches aim to provide non-invasive, repeatable testing options, which are highly valuable for long-term patient monitoring. The pipeline also includes AI-driven platforms designed to enhance data interpretation and reduce diagnostic errors, indicating a strong future trajectory for technological advancement.

Competitive Landscape

Abbott Laboratories

Guardant Health focuses on liquid biopsy technologies and is expanding its MRD capabilities through advanced ctDNA-based platforms. Its strong emphasis on non-invasive diagnostics positions it competitively in the oncology testing space.

Freenome Holdings, Inc.

Freenome is leveraging multi-omics and AI-driven approaches to enhance early cancer detection and MRD analysis. The company’s innovation-driven strategy supports its growing presence in precision diagnostics.

Adaptive Biotechnologies Corp.

Adaptive Biotechnologies specializes in immune-driven MRD detection using sequencing technologies. Its platforms are widely used in hematological malignancies, strengthening its market position.

Bio-Rad Laboratories, Inc.

Bio-Rad offers a range of PCR-based MRD testing solutions and continues to innovate in digital PCR technologies. Its strong product portfolio supports widespread clinical adoption.

NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals focuses on integrating MRD insights into therapeutic development. Its research-driven approach supports advancements in oncology treatment strategies.

Myriad Genetics, Inc.

Myriad Genetics is expanding its oncology diagnostics portfolio, including MRD-related solutions. Its established presence in genetic testing enhances its competitive positioning.

F. Hoffmann-La Roche AG

Roche is a global leader in diagnostics with a strong focus on molecular testing and MRD solutions. Its integrated platforms and extensive distribution network drive market leadership.

Sysmex Corporation

Sysmex specializes in hematology diagnostics and flow cytometry-based MRD testing. Its technological expertise supports its role in clinical diagnostics.

Invitae Corporation

Invitae focuses on genetic testing and is expanding into oncology diagnostics, including MRD applications. Its scalable testing platforms support a broader market reach.

Tempus Labs, Inc.

Tempus Labs integrates AI and genomic data to enhance MRD detection and oncology insights. Its data-driven approach strengthens its competitive edge.

Key Developments

• February 2026: The new RaDaR ST ctDNA assay, which was launched by NeoGenomics, enables hospitals to conduct precise MRD tests that meet Medicare standards for their initial purposes. NeoGenomics positions itself to capture a market worth over 20 billion dollars, which is expected to expand at 30 percent yearly.

• February 2026: Quest Diagnostics launched its Flow Cytometry MRD test for Myeloma as a blood test that detects multiple myeloma with the same accuracy as NGS tests, yet costs less and is more accessible to users. The product demonstrates five days of stability for specimen samples, which can be collected at more than 7000 phlebotomy locations throughout the United States to assist both medical professionals and research studies.

• January 2026: Myriad Genetics announced its path to commercialize Precise MRD™, which will begin as a research tool and transition into its first clinical testing phase in March 2026 for breast, colorectal, and renal cancer patients. The study demonstrates that ultrasensitive ctDNA detection can identify cancer recurrence at a concentration level of 1 ppm, which applies to both colorectal and breast cancer cases.

• June 2025: QIAGEN added new MRD testing capabilities through its partnerships with Tracer Biotechnologies, which offers digital PCR tests for solid tumors, and Foresight Diagnostics, which provides a kit version of its CLARITY™ NGS assay for lymphoma testing. QIAGEN now strengthens its position in companion diagnostic testing and decentralized MRD testing through its partnership with QIAcuity digital PCR technology.

Strategic Insights and Future Market Outlook

The MRD testing market is transitioning into a critical pillar of precision oncology, driven by its ability to provide actionable insights for treatment optimization. Companies are increasingly focusing on developing highly sensitive, scalable, and cost-effective solutions to meet growing clinical demand. Strategic collaborations between diagnostic firms and pharmaceutical companies are expected to accelerate innovation and market penetration.

Looking ahead, the integration of MRD testing into routine clinical workflows will be a key growth driver. The expansion into solid tumor applications and the adoption of liquid biopsy technologies will further broaden the market scope. Additionally, advancements in AI and data analytics will enhance diagnostic accuracy and efficiency, reinforcing the value of MRD testing in improving patient outcomes.

The Minimal Residual Disease Testing Market is poised for sustained growth as technological advancements, regulatory support, and increasing clinical adoption converge to reshape oncology diagnostics, making MRD testing an indispensable tool in modern cancer care.

Minimal Residual Disease Testing Market Scope: